Vaccine-Preventable Disease Surveillance in Kentucky by Jay, Katherine
University of Kentucky 
UKnowledge 
Theses and Dissertations--Public Health (M.P.H. 
& Dr.P.H.) College of Public Health 
2017 
Vaccine-Preventable Disease Surveillance in Kentucky 
Katherine Jay 
University of Kentucky, katherine.jay@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/cph_etds 
 Part of the Public Health Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Jay, Katherine, "Vaccine-Preventable Disease Surveillance in Kentucky" (2017). Theses and Dissertations--
Public Health (M.P.H. & Dr.P.H.). 166. 
https://uknowledge.uky.edu/cph_etds/166 
This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my capstone and abstract are my original work. Proper attribution has been 
given to all outside sources. I understand that I am solely responsible for obtaining any needed 
copyright permissions. I have obtained needed written permission statement(s) from the 
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic 
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to 
UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s capstone including 
all changes required by the advisory committee. The undersigned agree to abide by the 
statements above. 
Katherine Jay, Student 
Steven Browning, PhD, MSPH, Committee Chair 
Corrine Williams, ScD, MS, Director of Graduate Studies 
 
Vaccine-Preventable Disease Surveillance in Kentucky 
 
Capstone Project Paper 
 
A paper submitted in partial fulfillment of the requirements for the degree of Master of 
Public Health in the University of Kentucky College of Public Health 
By  
Katherine Jay 
Lexington, Kentucky 
May 24, 2017 
 
 
_____________________________________ 
Steven R. Browning, PhD, MSPH, Chair 
 
 
 
_____________________________________ 
Lorie Wayne Chesnut, DrPH, MPH 
 
 
  
_____________________________________ 
Kathleen Winter, PhD, MPH 
 2 
Contents 
Abstract……………………………………………………………………………………4 
Introduction………………………………………………………………………………..5 
 Vaccine-Preventable Disease Surveillance………………………………………..5 
 Hepatitis B………………………………………………………………………...8 
 Pertussis …………………………………………………………………………..9 
Methods……………………………………………………………………………..….…9 
Report……………………………………………………………………………………12 
Diphtheria………………………………………………………………………..12 
Haemophilus influenzae………………………………………………..………..15 
Hepatitis A………………………………………………………………………19 
Hepatitis B, Acute………………………………………………………….……22 
Hepatitis B, Chronic………………………………….…………………….……27 
Measles……………………………………………………………………….…30 
Meningococcal disease……………………………………………………….…34 
Mumps…………………………………………………………………………..37 
Pertussis ……………………………………………………………………..….40 
Poliovirus infection…………………………………………………...……..…..47 
Rubella…………………………………………………………………………..49 
Tetanus…………………………………………………………………………  55 
Varicella……………………………………………………………………..…..57 
Discussion……………………………………………………………………...…..……60 
Hepatitis B, Acute…………………………………………………..………...…60 
 3 
Pertussis………………………………………………………………..………..62 
Surveillance in Kentucky………………………………………………..………63 
References……………………………………………………………………..………..66 
Acknowledgments……………………………………………………………..….…….70 
Biographical Sketch…………………………………………………………...…….…..71 
  
 4 
Abstract 
Background: Vaccine-preventable disease (VPD) surveillance is important component to 
the success of vaccines. This report examines the levels of 13 of these VPDs in the state 
of Kentucky from 2005 to 2015.  
Methods: All reported cases in the state of Kentucky for the years 2005 to 2015 of 13 
vaccine-preventable diseases were obtained from the Disease Surveillance Module 
(DSM) and the National Electronic Disease Surveillance System (NEDSS). Where 
enough cases were reported, descriptive statistics were prepared. For acute hepatitis B 
and pertussis, more thorough analysis was performed.  
Results: Rates of acute hepatitis B in Kentucky from 2005 to 2015 were higher than the 
rates seen overall in the United States. Rates of pertussis over the same period were more 
similar to national trends. 
Conclusion: Changes to VPD surveillance in Kentucky would allow for a more thorough 
and informative report. An increased focus on collection of demographic data as well as 
risk factors would greatly improve future reports.  
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Introduction 
Vaccine-Preventable Disease Surveillance 
Vaccine-preventable diseases (VPDs) have long been an essential focus of public 
health in the United States. Prior to the development and wide-spread use of vaccines, 
many diseases that are rarely seen today had high morbidity and mortality. For example, 
in 1921 more than 15,000 Americans died from diphtheria.1 An effective vaccine was 
developed for diphtheria in the 1920s2 and today, only one case has been reported to the 
Centers for Disease Control and Prevention (CDC) since 2004.1 Vaccine-preventable 
diseases also have costs outside of their morbidity and mortality. These include societal 
and economic costs3 as well as missing school and work, visiting the doctor, and 
hospitalizations.4,5 While many vaccines have been very successful in controlling or even 
eliminating certain diseases, continuing to monitor the levels of these illnesses remains 
necessary to their continued control. 
While many vaccines have seen great success in controlling vaccine-preventable 
diseases,5 immunization and the study of these diseases remains an important focus of 
public health. Some diseases, while at low levels in the United States, have not truly been 
eliminated and are still found elsewhere in the world. This means that these diseases can 
still be imported into the United States through travel. Measles transmission has been 
considered to be interrupted in the United States since a record low number of cases was 
reported in 2004.2 However, cases of measles continue to be seen in the U.S. after being 
imported from countries where the disease is still endemic.2 This underscores the 
importance of maintaining high levels of vaccination, even when numbers of cases are 
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low. When populations or groups of people are under-immunized, it opens the door for 
outbreaks of these preventable diseases. It also puts people who are unable to be 
vaccinated at increased risk of encountering a vaccine-preventable disease.1 Despite all 
this, vaccine coverage has not always been high and vaccination in the United States has 
not always been a requirement, even when effective vaccines were available.   
A national survey conducted in 1941 examined attitudes of the American people 
towards immunizations to gauge readiness for compulsory immunizations for the public.6 
Immunizations were already required for those in the armed forces, and it was recognized 
that immunizing the public would help protect them from the increased possibility of the 
spread of communicable diseases during wartime.6 The results of this survey showed that 
only half of the population in need of vaccination were willing to be immunized.  The 
results also showed that the public was not well informed about vaccinations overall.6 It 
was not until a surge in the number of polio cases between the early 1940s and 1952 that 
attitudes really began to change.7  
Vaccine-preventable disease surveillance grew as national programs for 
immunization were developed. One of the early examples of surveillance of VPDs came 
after the inactivated poliomyelitis vaccine was licensed in 1955.2 The Poliomyelitis 
Surveillance Unit was established by the then-CDC in response to cases of paralytic 
poliomyelitis following vaccination, just days after the first case was recognized. Special 
officers for polio reporting were designated and were responsible for reporting cases of 
poliomyelitis in vaccinated individuals, as well as cases of family members and close 
contacts. The data were collected by the Poliomyelitis Surveillance Unit and 
disseminated in surveillance reports, with the first report being released only three days 
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after the surveillance was started. This swift surveillance allowed for the recognition that 
the problem was associated only with vaccine produced by a single manufacturer. Not 
only did this realization remove dangerous vaccines from the market, it also allowed 
continuous vaccination with the safely produced vaccines. This was an early case of 
modern surveillance, where data were collected and rapidly distributed after analysis, 
instead of just being archived.8 
Since the beginning of this new type of surveillance, technology has streamlined 
and increased the effectiveness of the process. Reporting of cases was originally done 
over the phone. Computer data systems, which were developed in the 1980’s, allowed 
reporting to be done electronically. Data were able to be reported through the National 
Electronic Telecommunications System for Surveillance (NETSS) starting in 1989. 
Beginning in 2000, federal funding was given to states to plan for and implement 
“integrated electronic systems for disease surveillance” which later became the National 
Electronic Disease Surveillance System (NEDSS), the system that is used to report 
diseases to the National Notifiable Disease Surveillance System (NNDSS) today. This 
system allows for easier and faster access to information related to case notifications, 
which includes both epidemiological and demographic information.8 
Notifiable diseases are reported to state and local health departments by 
healthcare providers, laboratories, and public health personnel. Since disease reporting 
requirements are mandated by the state, diseases that are reportable differ from state to 
state. For selected diseases, state health departments send notifications of cases to the 
CDC through NEDSS and the NNDSS.8 Because of the difference in reporting 
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requirements between states, it is important to look at vaccine-preventable diseases at the 
state level and not just nationally.  
Hepatitis B 
Groups at the highest risk of hepatitis B are those where contact with blood from 
infected persons is frequent or more likely. In the United States, one of the most 
important modes of transmission is perinatal because the likelihood of transmission from 
infected mother to child at birth is very high without appropriate post-exposure 
prophylaxis. Sexual contact with an infected person is another important mode of 
transmission.2 
Risk factors associated with infection are unprotected sex with an infected 
partner, multiple partners, men who have sex with men, history of other STDs, and 
injection drug use. Household contact with an infected person and exposure to hepatitis B 
virus infected blood or body fluids in the healthcare setting are also risk factors. 2,9 
Overall, incidence in the United States of acute hepatitis B has remained stable at 
around 1 case per 100,000 persons from 2006 to 2014.10-12 Over this same time period, 
Kentucky has seen an increase in the rate of hepatitis B for every year except 2014. The 
highest rate was seen in 2013 with 4.9 cases per 100,000.10,12 A study looking at HBV 
infection in three similar states (Kentucky, West Virginia, and Tennessee) saw an 
increase in incident cases of HBV among non-Hispanic whites with injection drug use as 
a common risk factor from 2009 to 2013, while rates remained stable in the United States 
overall. 11 
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Pertussis 
Infants under one year of age are at the greatest risk of hospitalization and death 
from pertussis, especially those who are too young to be vaccinated.2  This age group has 
the highest rate of pertussis in the United States overall, as well as in Kentucky.13,14 
United States pertussis incidence peaks every 3 to 5 years as the number of 
individuals in the population who are susceptible to pertussis increases. Immunity 
conferred by the acellular pertussis vaccine wanes more quickly than the previously used 
whole-cell vaccine. This is contributing to the changing epidemiology of pertussis, with 
an increasing number of cases being seen in previously vaccinated adolescents.15 
The purpose of this project is to generate a comprehensive report that describes 
the epidemiology of 13 VPDs in the state of Kentucky from 2005 to 2015. The diseases 
to be included in the report are diphtheria, Haemophilus influenzae disease, hepatitis A, 
acute hepatitis B, chronic hepatitis B, measles, meningococcal disease, mumps, pertussis, 
poliovirus infection, rubella, tetanus, and varicella. Special attention will be paid to acute 
hepatitis B and pertussis due to the large volume of cases seen over the specified time 
period. This report will allow for the examination of past trends in these preventable 
diseases and will be important to examining how these trends change going forward.  
Methods 
The data for this report were obtained from the Kentucky Department for Public 
Health and came from both the Disease Surveillance Module (DSM) and the National 
Electronic Disease Surveillance System (NEDSS). The DSM was used for disease 
surveillance and reporting in Kentucky prior to the adoption of NEDSS.16 NEDSS is an 
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online framework that supports the National Notifiable Disease Surveillance System 
(NNDSS). NEDSS allows for electronic data exchanges as well as case notifications. 
NEDSS also helps with the reporting of diseases by connecting the healthcare system to 
health departments, and those health departments to the CDC.17  
The de-identified data contained all reported cases in the state of Kentucky for the 
years 2005 to 2015 of 13 different vaccine-preventable diseases. The diseases included in 
the data were diphtheria, invasive Haemophilus influenzae disease, hepatitis A, acute 
hepatitis B infection, chronic hepatitis B infection, measles, meningococcal disease, 
mumps, pertussis, poliovirus infection, rubella, tetanus, and varicella. The data from 2005 
to 2012 came from the DSM, and the data from 2011 to 2015 came from NEDSS, with 
the overlapping years containing data from both sources. The two sets were merged to 
create a single dataset with all cases from 2005 to 2015. 
The data contained many missing values, which were accounted for in different 
ways depending on the variable. Any records missing a confirmed disease condition were 
removed. For cases where age was missing, an age was calculated by using the date of 
birth and the Morbidity and Mortality Weekly Report (MMWR) Year. MMWR Year is a 
variable that indicates what year the case was reported. Sixty-four records were missing 
both age and date of birth and were removed because an age was unable to be calculated, 
and age was a necessary variable for the report. For cases with missing state, the state 
was assumed to be Kentucky per instructions from the KDPH. 
Each record contained multiple variables relating to when the case happened or 
was reported. These include MMWR Year, Reported Year, and Case Confirm Date. In 
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most cases where all three of these variables were non-missing, they all had the same 
year and were therefore interchangeable to determine the year for the report. For 
consistency, MMWR Year was used when available. If MMWR Year was missing, then 
Reported Year was used. One record was missing both MMWR Year and Reported Year, 
so Case Confirm Date was used.  
Race and ethnicity were missing for a large number of records. These values were 
coded as missing, but cases were not excluded based on missing race or ethnicity because 
of the large number of missing values in these variables.  
Case Determination is a variable that was used to determine whether a reported 
case was actually a case of the disease. Twenty-two records were excluded due to 
missing case determination.  
The data contained many duplicate records. Since data was de-identified and 
name could not be used to confirm duplicates, duplicate entries that matched on three 
separate variables were considered the same case and collapsed into one entry. The three 
variables used were Date of Birth, County, and Date Diagnosed. If Date Diagnosed was 
missing, then Case Confirm Date, or MMWR Week and MMWR Year were used. 
For rate calculations, population estimates were obtained from the National 
Center for Health Statistics (NCHS). 
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Report 
Diphtheria 
Background2 
Diphtheria is caused by Corynebacterium diphtheria, an aerobic gram-positive 
bacterium. The bacteria itself must be infected with a specific virus that contains genetic 
information to produce toxin. Only these toxigenic strains of the bacteria cause severe 
disease. 
Diphtheria infection is classified based on infection site. Toxigenic diphtheria bacilli 
in any mucous membrane of a susceptible individual will produce a toxin that inhibits the 
synthesis of proteins in cells. This toxin destroys tissue at the site of infection and causes 
the formation of a pseudomembrane. The toxin can also be absorbed into the bloodstream 
and spread throughout the body, leading to complications like myocarditis, neuritis, and 
death. The most common infection sites are pharyngeal and tonsillar, where the 
pseudomembrane can cause respiratory obstruction.  
Diphtheria is usually spread person-to-person via the respiratory tract, although 
transmission can also occur through contact with discharge from skin lesions of an 
infected person. Diphtheria has an incubation period of 2 to 5 days with a range of 1 to 10 
days. The case fatality rate is 5 to 10%. For certain age groups (less than 5 years of age 
and greater than 40 years of age) the case fatality can be as high as 20%.  
Diphtheria toxoid was developed in the early 1920s and began being widely used in 
the 1930s. The toxoid is available in combination as pediatric diphtheria-tetanus toxoid 
(DT) or adult tetanus-diphtheria (Td). It is also combined with tetanus toxoid and the 
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pertussis vaccine as DTaP and Tdap. The usual vaccine schedule for children is 3 or 4 
doses and a booster, as well as boosters every 10 years. Doses should be given at 2, 4, 6, 
and 15 to 18 months of age with a booster at ages 4 to 6 years. 
Epidemiology 
Prior to development and widespread use of the diphtheria toxoid, diphtheria was a 
major cause of morbidity and mortality. In the United States in 1921, there were more 
than 200,000 cases reported, with 5% to 10% of cases being fatal.i Numbers of cases and 
deaths began to decrease gradually after the toxoid was developed. When the diphtheria 
toxoid began to be used more widely in the 1940s, numbers of cases decreased more 
rapidly. Diphtheria is now very rare in the United States.i From 1998 to 2004, only seven 
cases were reported.ii The toxigenic bacterium that causes diphtheria still circulates in 
parts of the country where the disease was previously endemic, which highlights the 
importance of continued vaccination.2  
Surveillance Case Definition (2001)8 
Probable: In the absence of a more likely diagnosis, an upper respiratory tract illness 
with an adherent membrane of the nose, pharynx, tonsils, or larynx; and absence of 
laboratory confirmation; and lack of epidemiologic linkage to a laboratory-confirmed 
case of diphtheria. 
Confirmed: An upper respiratory tract illness with an adherent membrane of the nose, 
pharynx, tonsils, or larynx; and any of the following: isolation of Corynebacterium 
diphtheriae from the nose or throat; or histopathologic diagnosis of diphtheria; or 
epidemiologic linkage to a laboratory-confirmed case of diphtheria. 
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Epidemiologic Summary 
No cases of diphtheria were reported in Kentucky between 2005 and 2015. 
Notes 
i: CDC. Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and 
other preventive measures: recommendations of the Immunization Practices Advisory 
Committee (ACIP). MMWR 1991;40(No. RR-10). 
ii: CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus 
toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations 
of the Advisory Committee on Immunization Practices (ACIP) and Recommendation 
of ACIP, supported by the Healthcare Infection Control Practices Advisory 
Committee (HICPAC), for Use of Tdap Among Health-Care Personnel. MMWR 
2006;55(No. RR-17). 
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Haemophilus influenzae 
Background2 
Haemophilus influenzae bacteria can cause severe infection, particularly in infants. 
There are six encapsulated strains (types a-f) as well as unencapsulated strains. All 
encapsulated strains can cause similar invasive disease, but only Haemophilus influenzae 
type b (Hib) is vaccine preventable. The polysaccharide capsule is an important virulence 
factor, unencapsulated strains rarely cause serious infection. Prior to vaccine 
development, type B caused 95% of invasive disease.  
The most common types of invasive disease caused by H. influenzae are meningitis, 
epiglottitis, pneumonia, arthritis, and cellulitis. It is most likely spread through 
respiratory droplets. 
The first conjugate vaccine for Hib was licensed in the United States in 1987. There 
are currently three conjugate vaccines currently licensed for use. All infants, including 
preterm infants, should receive a primary series of the Hib vaccine beginning at 2 months 
of age. The primary series contains either 2 or 3 doses depending on which vaccine is 
used, with a booster at 12 to 15 months of age for both vaccines. The vaccine is not 
recommended for children younger than 6 weeks of age because doses given at this time 
may reduce the response to doses given later.  
Epidemiology 
Before effective vaccines were introduced in the 1980s, one in 200 children less than 
5 years old developed invasive Hib disease.i Incidence of Hib disease has decreased by 
more than 99% since the licensure of conjugate Hib vaccine.ii  
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Surveillance Case Definition (2014)8 
Clinical case description 
Invasive disease caused by H. influenzae can produce any of several clinical 
syndromes, including meningitis, bacteremia, epiglottitis, pneumonia, septic 
arthritis, cellulitis, or purulent pericarditis; endocarditis and osteomyelitis occur 
less commonly. 
Laboratory criteria for diagnosis 
• Detection of Haemophilus influenzae type b antigen in cerebrospinal fluid 
[CSF] 
• Detection of Haemophilus influenzae-specific nucleic acid in a specimen 
obtained from a normally sterile body site (e.g., blood or CSF), using a 
validated polymerase chain reaction (PCR) assay 
OR 
• Isolation of H. influenzae from a normally sterile body site (e.g., CSF, blood, 
joint fluid, pleural fluid, or pericardial fluid) 
Case classification 
Probable: Meningitis with detection of H. influenzae type b antigen in 
cerebralspinal fluid [CSF] 
Confirmed: 
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• Isolation of H. influenzae from a normally sterile body site (e.g., 
cerebrospinal fluid [CSF], blood, joint fluid, pleural fluid, pericardial 
fluid) 
OR 
• Detection of Haemophilus influenzae -specific nucleic acid in a specimen 
obtained from a normally sterile body site (e.g., cerebrospinal fluid [CSF], 
blood, joint fluid, pleural fluid, pericardial fluid), using a validated 
polymerase chain reaction (PCR) assay 
Epidemiologic Summary 
There were a total of 288 reported cases of invasive Haemophilus influenzae disease in 
the state from 2005 to 2015.  
Notes 
i: Bisgard KM, Kao A, Leake J, et al. Haemophilus influenzae invasive disease in the 
United States, 1994-1995: near disappearance of a vaccine-preventable childhood 
disease. Emerg Infect Dis 1998;4:229-37. 
ii: MacNeil JR et al; Current Epidemiology and Trends in Invasive Haemophilus 
influenzae Disease - United States, 1989-2008. Clinical Infectious Diseases; 
2011;53(12):1230-6 
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Table 1. Reported invasive Haemophilus influenzae disease cases by age, race, ethnicity, 
and sex –Kentucky, 2005-2015 
 Cases Percent of Cases 
Age   
<12 mos  18 6.25 
1-14 years  34 11.81 
15-24 5 1.74 
25-44 21 7.29 
45-64 55 19.10 
65-74 60 20.83 
75-84 59 20.49 
85+ 36 12.50 
Race   
American Indian or Alaska Native - - 
Asian and Pacific Islander 1 0.35 
Black or African American 18 6.25 
Other, Multi 1 0.35 
Unknown 18 6.25 
White 198 68.75 
Missing 52 18.06 
Ethnicity   
Hispanic or Latino 2 0.69 
Not Hispanic or Latino 138 47.92 
Unknown 2 0.69 
Missing 146 50.70 
Sex   
Female 150 52.08 
Male 129 44.79 
Unknown 9 3.13 
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Hepatitis A 
Background2 
Hepatitis A is caused by hepatitis A virus (HAV), which is a nonenveloped RNA 
picornavirus. HAV is spread through fecal-oral transmission and is acquired by mouth 
usually through ingesting contaminated food or water. Hepatitis A presents similarly to 
other acute viral hepatitis infections. Symptoms include sudden onset of fever, malaise, 
anorexia, nausea, abdominal discomfort, dark urine, and jaundice. Children less than six 
years of age are more likely to be asymptomatic. For older children and adults, the 
infection usually shows symptoms. Jaundice occurs in 70% of patients in this group. The 
incubation period of hepatitis A is 28 days, with a range of 15 to 50 days. The hepatitis A 
vaccine is recommended for all children at 1 year of age as well as individuals at 
increased risk of infection. This includes individuals traveling to areas where hepatitis A 
is common, those who are in close contact with an adoptee from a country where 
hepatitis A is common, men who have sex with men, injection and non injection drug 
users, individuals with clotting factor disorders, and individuals with occupational risk of 
exposure. Occupational risk is defined as individuals who work with hepatitis A infected 
primates or work with the virus in a laboratory setting. No other groups have been shown 
to have increased risk of infection due to occupational exposures. 
Epidemiology 
Rates of hepatitis A have been decreasing since 1996 when vaccination was initiated.i 
Rates of hepatitis A have declined by 95% since the vaccine first became available.ii 
Surveillance Case Definition (2000)8 
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Clinical Criteria 
An acute illness with a) discrete onset of symptoms and b) jaundice, elevated 
serum aminotransferase levels (ALT or AST) 
Laboratory criteria 
Immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive 
Case classification 
Confirmed: a case that meets the clinical case definition and is laboratory 
confirmed or a case that meets the clinical case definition and occurs in a person 
who has an epidemiologic link with a person who has laboratory-confirmed 
hepatitis A (i.e., household or sexual contact with an infected person during the 
15-50 days before the onset of symptoms). 
Epidemiologic Summary 
There were 242 cases of hepatitis A reported in Kentucky between 2005 and 2015.  
Notes 
i: CDC. Prevention of hepatitis A through active or passive immunization: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR 2006;55(No. RR-7) 
ii: CDC. Hepatitis A Questions and Answers for Health Professionals. 
https://www.cdc.gov/hepatitis/hav/havfaq.htm#general. Accessed June 20, 2017.  
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Table 2. Reported hepatitis A cases by age, race, ethnicity, and sex –Kentucky, 2005-
2015 
 Cases Percent of Cases 
Total   
Kentucky 242 - 
Age   
0-9 30 12.40 
10-19 21 8.68 
20-29 37 15.29 
30-39 26 10.74 
40-49 30 12.40 
50-59 39 16.12 
60+ 59 24.38 
Race   
American Indian or Alaska Native - - 
Asian and Pacific Islander 3 1.24 
Black or African American 7 2.89 
Other, Multi - - 
Unknown 27 11.16 
White 121 50.00 
Missing 84 34.71 
Ethnicity   
Hispanic or Latino 17 7.02 
Not Hispanic or Latino 131 54.13 
Unknown 23 9.50 
Missing 71 29.34 
Sex   
Female 121 50.00 
Male 118 48.76 
Unknown 3 1.24 
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Hepatitis B, Acute 
Background2 
Hepatitis B is caused by hepatitis B virus and is transmitted through contact with 
blood or other body fluids that are infected. Important routes of transmission, especially 
in the United States, are perinatal, sexual contact, and injection drug use. Adults are more 
likely to show symptoms than children and infants, but at least 50% of infections in 
adults are asymptomatic. If symptoms are present they are not specific to hepatitis B and 
can include malaise, fever, headache, and muscle pain. Some individuals may progress to 
chronic infection, which is discussed in the Hepatitis B, Chronic portion of this report. 
The virus has an incubation period of 45 to 160 days with an average of 120 days. 
Vaccination is recommended for all children. The vaccine is given in 3 doses, with the 
first dose given soon after birth before leaving the hospital. This vaccine has an efficacy 
of 95% in infants and children and 90% in adults. Antibody levels decline with time but 
remain intact for more than 20 years, so boosters are not recommended. 
Epidemiology 
Hepatitis B became reportable in the United States in the 1970s.2 Incidence peaked in 
the mid 1980s with around 26,000 cases reported annually.i Since that time, the number 
of cases has decreased.i Acute hepatitis B incidence decreased by 75% from 1990 to 
2005. The largest decrease in this time was 96% and was seen in children and 
adolescents, which coincides with increased vaccine coverage during this same time 
period.ii 
Surveillance Case Definition (2000)8 
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Clinical case definition 
An acute illness with 
• A discrete onset of symptoms, and 
• Jaundice or elevated serum aminotransferase levels 
Laboratory criteria for diagnosis 
• IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B 
surface antigen (HBsAg) positive 
• IgM anti-HAV negative (if done) 
Case classification 
Confirmed: A case that meets the clinical case definition and is laboratory 
confirmed. 
Epidemiologic Summary 
There were 1,377 cases of acute Hepatitis B reported in Kentucky between 2005 and 
2015.  
Notes 
i: CDC. Reported number and rate per 100,000 population of cases of acute, 
symptomatic, viral hepatitis, by type and year, United States, 1966-2008.  
https://www.cdc.gov/hepatitis/statistics/2008surveillance/table1b.htm. Accessed June 20, 
2017. 
ii: CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B 
virus infection in the United States. Recommendations of the Advisory Committee on 
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Immunization Practices (ACIP) Part II: Immunization of Adults. MMWR 2006;55(No. 
RR-16):1–33. 
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Table 3. Rate of hepatitis B, acute by year per 100,000 
  2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Hepatitis 
B, Acute 1.60 1.68 1.76 2.35 2.15 3.13 3.37 3.99 4.77 3.29 3.55 
Rates based on population estimates obtained from National Center for Health Statistics 
(NCHS)18 
Table 4. Reported acute hepatitis B cases by age, race, ethnicity, and sex –Kentucky, 
2005-2015 
 Cases Rate per 100,000 Rate Ratio 95% CI 
Total     
Kentucky 1377 2.89 - - 
Age     
<19 7 0.06 ref - 
20-29 195 3.04 54.12 (25.46, 115.04) 
30-39 481 7.76 138.25 (65.55, 291.55) 
40-49 406 6.04 107.58 (50.96, 227.11) 
>50 288 1.82 32.45 (15.33, 68.69) 
Race     
American Indian or Alaska 
Native 
4 2.89 1.48 (0.56, 3.96) 
Asian and Pacific Islander 3 0.46 0.24 (0.08, 0.74) 
Black or African American 54 1.35 0.69 (0.52, 0.91) 
White 834 1.95 ref - 
Other, Multi 3 - - - 
Unknown 237 - - - 
Missing 242 - - - 
Ethnicity     
Hispanic or Latino 12 0.85 0.50 (0.29, 0.89) 
Not Hispanic or Latino 777 1.68 ref - 
Unknown 199 - - - 
Missing 389 - - - 
Sex     
Female 590 2.44 ref - 
Male 771 3.29 1.35 (1.21, 1.50) 
Unknown 15 - - - 
Missing 1 - - - 
Rates based on population estimates obtained from National Center for Health Statistics 
(NCHS)18  
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Table 5. Rate of hepatitis B, acute by area development district per 100,000 
Area development 
district Rate 
Barren River 1.73 
Big Sandy 12.21 
Bluegrass 1.96 
Buffalo Trace 4.20 
Cumberland Valley 7.15 
Fivco 4.32 
Gateway 4.35 
Green River 0.85 
Kentucky River 5.12 
KIPDA 1.60 
Lake Cumberland 2.07 
Lincoln Trail 1.33 
Northern Kentucky 4.71 
Pennyrile 1.92 
Purchase 1.07 
Rates based on population estimates obtained from National Center for Health Statistics 
(NCHS)18	
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Hepatitis B, Chronic 
Background2 
 Acute infection with hepatitis B virus (HBV) can progress to a chronic infection. 
Chronic hepatitis B is responsible for most of the morbidity and mortality associated with 
HBV. The proportion of patients who will progress to chronic disease varies depending 
on factors such as age and immune status. Of infants who acquire HBV from their 
mothers or during childhood, 90% become chronically infected. Of those infected 
between 1 and 5 years, 30-50% become chronically infected and 5% of adults become 
chronically infected. Chronic infection may not show any symptoms but can still infect 
others. HBV related illnesses caused by chronic infection include chronic hepatitis, 
cirrhosis, liver failure, and hepatocellular carcinoma. In more than 25% of carriers, 
chronic active hepatitis develops which can often result in cirrhosis.  
Surveillance Case Definition (2007)8 
Clinical description 
Persons with chronic HBV infection may have no evidence of liver disease or may 
have a spectrum of disease ranging from chronic hepatitis to cirrhosis or liver 
cancer. Persons with chronic infection may be asymptomatic. 
Laboratory criteria for diagnosis 
• IgM anti-HBc negative AND a positive result on one of the following tests: 
HBsAg, HBeAg, or HBV DNA OR 
• HBsAg positive or HBV DNA positive or HBeAg positive two times at least 6 
months apart (Any combination of these tests performed 6 months apart is 
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acceptable.) 
Case classification 
Confirmed: a case that meets either laboratory criterion for diagnosis 
Probable: a case with a single HBsAg-positive or HBV DNA-positive or HBeAg-
positive laboratory result when no IgM anti-HBc results are available 
Comment: Multiple laboratory tests indicative of chronic HBV infection may be 
performed simultaneously on the same patient specimen as part of a “hepatitis panel.” 
Testing performed in this manner may lead to seemingly discordant results, e.g., 
HBsAg negative AND HBV DNA positive. For purposes of this case definition, any 
positive result among the three laboratory tests mentioned above is acceptable, 
regardless of other testing results. Negative HBeAg results and HBV DNA levels 
below positive cutoff level do not confirm the absence of HBV infection. 
Epidemiologic Summary 
There were 109 cases of chronic hepatitis B reported in Kentucky between 2011 and 
2015. 
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Table 6. Reported chronic hepatitis B cases by age, race, ethnicity, and sex –Kentucky, 
2011-2015 
 Cases Percent of Cases 
Total   
Kentucky 109 - 
Age   
0-9 2 1.83 
10-19 2 1.83 
20-29 25 22.94 
30-39 33 30.28 
40-49 19 17.43 
50-59 19 17.43 
60+ 9 8.26 
Race   
American Indian or Alaska Native - - 
Asian and Pacific Islander 3 2.75 
Black or African American 3 2.75 
Other, Multi - - 
Unknown 61 55.96 
White 34 31.19 
Missing 8 7.34 
Ethnicity   
Hispanic or Latino - - 
Not Hispanic or Latino 31 28.44 
Unknown 62 56.88 
Missing 16 14.68 
Sex   
Female 65 59.63 
Male 44 40.37 
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Measles  
Background2 
Measles is a highly communicable viral illness. The secondary attack rate, or 
frequency of cases among susceptible contacts of an infected individual, is nearly 90%. 
Measles is transmitted through respiratory droplets from person to person. The incubation 
period is 10 to 12 days from exposure to the first sign of illness and 14 days from 
exposure to the onset of rash, with a range of 7 to 21 days. The symptoms include an 
increasing fever, cough, and runny nose, followed by a rash that begins on the face and 
neck.  
The measles vaccine currently available in the United States is combined with the 
vaccines for mumps and rubella (MMR) or combined with the vaccines for mumps, 
rubella, and varicella (MMRV). Two doses of the vaccine containing the measles vaccine 
are recommended for all children 12 months of age or older. The two doses should be 
separated by at least 4 weeks, although the second dose is routinely given at age 4 to 6. 
The vaccine series confers lifelong immunity and has an efficacy of 95% when given at 
12 months and 98% when given at 15 months. 
Epidemiology 
Before the development and licensing of a measles vaccine in 1963, infection during 
childhood was nearly universal. At that time there were an average of 400,000 cases 
reported each year, although the actual number of cases was estimated to be much higher 
at 3 to 4 million cases per year.i Since 1963, there has been a dramatic 99% decrease in 
measles incidence. There was a resurgence of measles from 1989 to 1991. During this 
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time there were more than 55,000 reported cases and 123 deaths. The main cause of this 
increase in cases was due to low vaccination coverage.i  
Following the resurgence, efforts to vaccinate children of preschool age were 
increased which caused a decrease in reported cases. Available data shows that measles 
transmission in the United States has been interrupted and the majority of cases are either 
imported from other countries or linked to imported cases.i The year 2008 saw the largest 
total measles cases in the country since 1996. This increase was not due to a higher 
number of cases being imported, but was due to increased transmission after the virus 
was imported among children who were able to be vaccinated but whose parents chose 
not to vaccinate them.ii In 2011, 16 outbreaks and 220 measles cases were reported. The 
majority of these were imported cases in unvaccinated individuals. Outbreaks were also 
seen in 2013, 2014, and 2015.iii 
Surveillance Case Definition (2012)8 
Clinical description: 
An acute illness characterized by: 
• generalized, maculopapular rash lasting ≥3 days; and 
• temperature ≥101°F or 38.3°C; and 
• cough, coryza, or conjunctivitis 
Probable: In the absence of a more likely diagnosis, an illness that meets the clinical 
description with 
• no epidemiologic linkage to a laboratory-confirmed measles case; and 
• noncontributory or no measles laboratory testing. 
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Confirmed: An acute febrile rash illness† with: 
• isolation of measles virus‡ from a clinical specimen; or 
• detection of measles virus-specific nucleic acid from a clinical specimen using by 
polymerase chain reaction; or 
• IgG seroconversion‡ or a significant rise in measles immunoglobulin G 
antibody‡using any evaluated and validated method; or 
• a positive serologic test for measles immunoglobulin M antibody‡ §; or 
• direct epidemiologic linkage to a case confirmed by one of the methods above. 
† Temperature does not need to reach ≥101°F/38.3°C and rash does not need to last ≥3 
days. 
‡ Not explained by MMR vaccination during the previous 6–45 days. 
§ Not otherwise ruled out by other confirmatory testing or more specific measles 
testing in a public health laboratory. 
Epidemiologic Summary 
There were two reported cases of measles in Kentucky between 2005 and 2015. 
Notes 
i: CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of 
measles, rubella, and congenital rubella syndrome and control of mumps: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR 1998;47(No. RR-8):1–57. 
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ii: CDC. Update: Measles—United States, January—July 2008. MMWR 2008;7(33);893-
896. 
iii: CDC. Measles Cases and Outbreaks.  https://www.cdc.gov/measles/cases-
outbreaks.html. Accessed June 20, 2017. 
  
 34 
Meningococcal disease 
Background2 
Meningococcal disease is caused by the bacterium Neisseria meningitidis. Invasive 
infection with this bacterium usually presents as meningitis and/or meningococcal sepsis. 
N. meningitidis has a polysaccharide capsule and is classified based on the structure of 
this capsule. There are thirteen serogroups, but nearly all invasive disease is caused by 
either A, B, C, W, or Y. The bacteria are transmitted by respiratory droplet or direct 
contact. It has an incubation period of 3 to 4 days with a range of 2 to 10 days. Up to 10% 
of adolescents and adults are asymptomatic transient carriers of the bacteria, usually of 
strains that are not pathogenic.   
The first vaccine was licensed in the United States in 1974. The current vaccine was 
licensed in 1981 and is quadrivalent, covering serogroups A, C, W, and Y. The vaccine is 
recommended at age 11 or 12 with a booster at age 16.  
Epidemiology 
Incidence of meningococcal disease peaked in the late 1990s.i Routine use of the 
meningococcal vaccine was recommended in 2005.2 Since this recommendation, 
incidence has decreased among all age groups. Incidence of disease caused by the 
serogroup not included in the vaccine (B), has also declined.i 
Surveillance Case Definition (2005)8 
Confirmed case: A confirmed case of meningococcal disease is defined by isolation of 
N. meningitidis from a normally sterile site (e.g., blood or cerebrospinal fluid [CSF]) 
from a person with clinically compatible illness. 
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Probable case: A probable case of meningococcal disease is defined by detection of 
N. meningitidis DNA by polymerase chain reaction or polysaccharide antigen in CSF 
(e.g., by latex agglutination or immunohistochemistry), or the presence of clinical 
purpura fulminans in the absence of diagnostic culture from a person with clinically 
compatible disease. 
Epidemiologic Summary 
There were 94 cases of meningococcal disease reported in Kentucky between 2005 and 
2015.  
Notes 
i: CDC. Prevention and Control of Meningococcal Disease: Recommendations of the 
Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62(No. RR-2):[1-
30]. 
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Table 7. Reported invasive meningococcal disease by age, race, ethnicity, and sex –
Kentucky, 2005-2015 
 Cases Percent of Cases 
Total   
Kentucky 94 - 
Age   
<1 11 11.70 
1-4 18 19.15 
5-10 9 9.57 
11-18 6 6.38 
19-24 8 8.51 
25-44 11 11.70 
45-64 13 13.83 
65+ 18 19.15 
Race   
American Indian or Alaska Native 1 1.06 
Asian and Pacific Islander - - 
Black or African American 10 10.64 
Other, Multi - - 
Unknown 2 2.13 
White 48 51.06 
Missing 33 35.11 
Ethnicity   
Hispanic or Latino 4 4.26 
Not Hispanic or Latino 56 59.57 
Unknown - - 
Missing 34 36.17 
Sex   
Female 49 52.13 
Male 43 45.74 
Unknown 2 2.13 
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Mumps 
Background2 
Mumps is caused by an RNA virus and is spread through respiratory droplets. The 
characteristic symptom of mumps is salivary gland inflammation, called parotitis. Rates 
of parotitis among all age groups ranges from 31% to 65%, although this can vary based 
on age and immunity. The incubation period is 12 to 25 days with parotitis usually 
developing 16 to 18 days after exposure to the virus. Mumps can cause very serious 
complications such as orchitis, oophoritis, aseptic meningitis, pancreatitis, and deafness. 
An inactivated mumps vaccine was first developed in 1948. The vaccine currently 
used was licensed in 1967 and was recommended for routine use beginning in 1977. The 
mumps vaccine is given as part of the combined measles, mumps, rubella (MMR) 
vaccine. The first dose is recommended when the child is at least 12 months old. The 
second dose is given between ages 4 and 6, before entering kindergarten or first grade. 
The two doses have an effectiveness of 88% and confer lifelong immunity.  
Epidemiology 
There were 185,691 cases of mumps reported in the United States in 1967.i After the 
mumps vaccine was licensed in 1967, there was a rapid decrease in reported cases. The 
number of mumps cases further declined when two doses of the vaccine were 
recommended, which decreased the rate of vaccine failure.i There were fewer than 270 
cases reported each year by the early 2000s.ii There was a large increase in cases in both 
2006 (6,584 cases reported) and 2009-2010 (3,503 and 505 cases reported in two separate 
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outbreaks) due to outbreaks, but these outbreaks were contained due to high vaccine 
coverage.ii  
Surveillance Case Definition (2011)8 
Suspect: 
• parotitis, acute salivary gland swelling, orchitis, or oophoritis unexplained by 
another more likely diagnosis, 
or 
• a positive lab result with no mumps clinical symptoms (with or without 
epidemiological linkage to a confirmed or probable case). 
Probable: 
• Acute parotitis or other salivary gland swelling lasting at least 2 days, or orchitis 
or oophoritis unexplained by another more likely diagnosis, in: 
o a person with a positive test for serum anti-mumps IgM antibody, or 
o a person with epidemiologic linkage to another probable or confirmed case or 
linkage to a group/community defined by public health during an outbreak of 
mumps. 
Confirmed: 
• A positive mumps laboratory confirmation for mumps virus with RT-PCR or 
culture in a patient with an acute illness characterized by any of the following: 
◦ Acute parotitis or other salivary gland swelling, lasting at least 2 days 
◦ Aseptic meningitis 
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◦ Encephalitis 
◦ Hearing loss 
◦ Orchitis 
◦ Oophoritis 
◦ Mastitis 
◦ Pancreatitis 
Epidemiologic Summary 
There were 6 cases of mumps reported in Kentucky between 2005 and 2015.  
Notes 
i: CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of 
measles, rubella, and congenital rubella syndrome and control of mumps. 
Recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR 1998;47(No. RR-8):1–57 
ii: CDC. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: 
summary recommendations of the Advisory Committee on Immunization Practices 
(ACIP), MMWR 2013:62(No. 4): 1-34. 
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Pertussis 
Background2 
Pertussis, also called whooping cough, is caused by the bacterium Bordetella 
pertussis. Pertussis has an incubation period of 7 to 10 days with a range of 4 to 21 days. 
Transmission occurs through contact with respiratory droplets of an infected individual. 
The illness presents with bursts of coughing which make it difficult to breath. The 
coughing attack is followed by a whooping sound when the individual attempts to inhale. 
Older individuals and children with partial protection from vaccination may become 
infected with the bacterium but may have a milder course of the disease than young 
children and infants. Although the disease may be milder in older individuals, they are 
still able to transmit the disease to susceptible individuals, such as infants who are too 
young to be immunized. Young infants are at the highest risk for complications from 
pertussis. The most common complication is secondary bacterial pneumonia. Pertussis is 
highly communicable. Among susceptible household contacts, pertussis has a secondary 
attack rate of 80%. 
The pertussis vaccine is included in DTaP combined with diphtheria and tetanus 
toxoids. The primary series of this vaccine has four doses. The first dose is recommended 
beginning at 6 weeks of age to two months, with the following two doses given in 4 to 8 
week intervals. The final dose is given 6 to 12 months after the third dose. A fifth booster 
dose is given before entering school if a child received all four doses of the primary series 
before turning 4. There is also an adult vaccine containing pertussis, diphtheria, and 
tetanus toxoids called Tdap. A single dose of this vaccine is recommended for ages 11 
through 18 years and 19 through 64 years. All pregnant women should receive a dose 
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between 27 and 36 weeks gestation during each pregnancy. Individuals who are going to 
be in contact with infants too young to be vaccinated (less than 6 weeks of age) should 
receive a single dose of Tdap if they have not previously. 
Epidemiology 
Pertussis was a common cause of childhood morbidity and mortality before the 
vaccine was licensed. An average of 200,000 cases were reported each year from 1943 to 
1943.i After the vaccine became routinely recommended in the 1940s, the number of 
reported cases decreased in the following decades. In 1976, a low of 1,010 cases were 
reported.i Incidence has been gradually increasing since the 1980s, although levels 
remain well below those seen in the pre-vaccine era.i 
Surveillance Case Definition (2014)8 
Clinical case definition 
In the absence of a more likely diagnosis a cough illness lasting ≥ 2 weeks with one 
of the following symptoms: 
• Paroxysms of coughing, OR 
• Inspiratory “whoop,” OR 
• Posttussive vomiting, OR 
• Apnea (with or without cyanosis) (FOR INFANTS AGED < 1 YEAR ONLY) 
Laboratory criteria for diagnosis 
• Isolation of B. pertussis from a clinical specimen 
• Positive polymerase chain reaction (PCR) assay for B. pertussis DNA 
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Epidemiologic Linkage 
• Contact with a laboratory-confirmed case of pertussis†*. 
Case classification 
Probable: 
• Meets the clinical case definition, is not laboratory confirmed, and is not 
epidemiologically linked to a laboratory-confirmed case OR 
• FOR INFANTS AGED < 1 YEAR ONLY: 
o Acute cough illness of any duration with at least one of the following signs or 
symptoms: 
§ Paroxysms of coughing, OR 
§ Inspiratory “whoop”, OR 
§ Posttussive vomiting, OR 
§ Apnea (with or without cyanosis) 
AND 
o Polymerase chain reaction (PCR) positive for pertussis, OR 
• FOR INFANTS AGED < 1 YEAR ONLY: 
o Acute cough illness of any duration with at least one of the following signs or 
symptoms: 
§ Paroxysms of coughing, OR 
§ Inspiratory “whoop”, OR 
§ Posttussive vomiting, OR 
§ Apnea (with or without cyanosis) 
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AND 
o Contact with a laboratory-confirmed case of pertussis 
Confirmed: 
• Acute cough illness of any duration with isolation of B. pertussis from a clinical 
specimen, OR 
• Meets the clinical case definition AND is polymerase chain reaction (PCR) 
positive for pertussis, OR 
• Meets the clinical case definition AND had contact with a case laboratory-
confirmed case of pertussis 
*Note: An illness meeting the clinical case definition should be classified as 
“probable” rather than “confirmed” if it occurs in a patient who has contact with an 
infant aged < 1 year who is polymerase chain reaction (PCR) positive for pertussis and 
has ≥ 1 sign or symptom and cough duration < 14 days (classified as “probable” case). 
†To confirm a case by epidemiologic linkage, the case must be directly linked (i.e., a 
first-generation contact) to a laboratory-confirmed case by either culture or PCR. 
Epidemiologic Summary 
There were 2,669 cases of pertussis reported in Kentucky between 2005 and 2015. 
Notes 
i: CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, 
reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of the 
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Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-
17):1-33. 
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Table 8. Rate of pertussis by year per 100,000 
  2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Pertussis 4.66 1.87 1.20 4.50 7.67 8.16 3.98 12.34 7.82 5.82 3.37 
Rates based on population estimates obtained from National Center for Health Statistics 
(NCHS)18 
 
Table 9. Reported pertussis cases by age, race, ethnicity, and sex –Kentucky, 2005-2015 
 Cases Rate per 100,000 Rate Ratio 95% CI 
Total     
Kentucky 2669 5.61 - - 
Age     
<1 503 81.70 64.83 (57.12, 73.57) 
1-3 414 22.62 17.95 (15.72, 20.50) 
4-6 216 11.69 9.28 (7.89, 10.91) 
7-9 407 22.05 17.50 (15.31, 19.996) 
10-17 670 13.29 10.55 (9.37, 11.88) 
>18 459 1.26 ref - 
Race     
American Indian or Alaska Native 1 0.72 0.22 (0.03, 1.53) 
Asian and Pacific Islander 12 1.85 0.55 (0.31, 0.97) 
Black or African American 84 2.09 0.62 (0.50, 0.78) 
White 1436 3.36 ref - 
Other, Multi 4 - - - 
Unknown 534 - - - 
Missing 598 - - - 
Ethnicity     
Hispanic or Latino 50 3.54 1.25 (0.94, 1.65) 
Not Hispanic or Latino 1310 2.84 ref - 
Unknown 445 - - - 
Missing 864 - - - 
Sex     
Female 1411 5.83 ref - 
Male 1199 5.12 0.88 (0.81, 0.95) 
Unknown 53 - - - 
Missing 6 - - - 
 
Rates based on population estimates obtained from National Center for Health Statistics 
(NCHS)18 
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Poliovirus infection 
Background2 
Poliovirus is an enterovirus with three different serotypes (P1, P2, and P3). For 
nonparalytic poliomyelitis, the incubation period is 3 to 6 days. In paralytic poliomyelitis, 
the incubation period for the onset of paralysis is 7 to 21 days. The response to infection 
with poliovirus varies greatly among individuals and is classified based on the severity of 
the clinical presentation. A large proportion of infected individuals (up to 72% of 
infections in children) do not show symptoms but can still shed virus and infect others. 
Poliovirus is spread through the fecal-oral route as well as the respiratory route. 
Inactivated polio vaccine (IPV) has been exclusively used in the United States since 
2000. The primary series consists of three doses, with the first dose given as early as six 
weeks of age. The second dose is given at 4 months of age and the third dose is given 
between 6 and 18 months of age. A final dose is given at four years or older.  
Epidemiology 
Transmission of wild poliovirus was interrupted in the United States in 1979.i 
Inactivated polio vaccine was introduced in 1955 and incidence of poliovirus infection 
greatly decreased after its introduction.i Monovalent oral poliovirus vaccines (MOPV) 
were introduced for all three types between 1961 and 1962. A trivalent OPV was licensed 
in 1963 and replaced the use of IPV. Since OPV can cause vaccine-associated paralytic 
polio, its use was discontinued in the United States in 2000 and replaced with IPV.2  
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Surveillance Case Definition (2010)8 
Case classification, Paralytic 
Probable: Acute onset of a flaccid paralysis of one or more limbs with decreased or 
absent tendon reflexes in the affected limbs, without other apparent cause, and 
without sensory or cognitive loss. 
Confirmed: Acute onset of a flaccid paralysis of one or more limbs with decreased or 
absent tendon reflexes in the affected limbs, without other apparent cause, and 
without sensory or cognitive loss; AND in which the patient 
• has a neurologic deficit 60 days after onset of initial symptoms, or 
• has died, or 
• has unknown follow-up status. 
Case classification, Non-paralytic 
Confirmed: Any person without symptoms of paralytic poliomyelitis in whom a 
poliovirus isolate was identified in an appropriate clinical specimen, with 
confirmatory typing and sequencing performed by the CDC Poliovirus laboratory, as 
needed. 
Epidemiologic Summary 
No cases of poliomyelitis were reported in Kentucky between 2005 and 2015.  
Notes 
i: CDC. Poliomyelitis prevention in the United States: updated recommendations of the 
Advisory Committee on Immunization Practices. (ACIP). MMWR 2000;49 (No. RR-5).  
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Rubella  
Background2 
Rubella is caused by an RNA virus and has an incubation period of 14 days with a 
range of 12 to 23 days. It is spread through respiratory droplets. Rubella often presents 
with mild symptoms, with up to half of infections being subclinical. In children, the first 
symptom is usually a rash. Rubella infection in pregnant women can have severe 
consequences. If a woman is infected with rubella during her pregnancy, especially 
during the first trimester, it can lead to congenital rubella syndrome (CRS). CRS can 
cause fetal death or premature delivery, as well as a number of birth defects such as 
deafness, eye defects, cardiac defects, neurological abnormalities, bone alterations, and 
damage to the liver and spleen. Deafness is the most common manifestation of CRS. 
The main goal of rubella vaccination programs in the United States is the prevention 
of CRS. The rubella vaccine is combined with measles and mumps vaccines as MMR or 
with measles, mumps, and varicella vaccines as MMRV. The first dose of rubella 
containing vaccine is recommended for all children at 12 months of age or older. The 
second dose should be given between ages 4 and 6 before starting kindergarten or first 
grade. The duration of immunity conferred by this vaccine is lifelong.  
Epidemiology 
In 1969, the United States saw its largest annual total of reported rubella cases with 
57,600 reported cases.i The incidence of rubella decreased rapidly after a vaccine was 
licensed in 1969, with only 12,400 cases reported in 1976.i Fewer than 1,000 cases per 
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year were reported by 1984.i In 2004, rubella was declared to no longer be endemic in the 
United States.2 
Rubella Surveillance Case Definition (2012)8 
Suspected: Any generalized rash illness of acute onset that does not meet the criteria 
for probable or confirmed rubella or any other illness. 
Probable: In the absence of a more likely diagnosis, an illness characterized by all of 
the following: 
• acute onset of generalized maculopapular rash; and 
• temperature greater than 99.0° F or 37.2° C, if measured; and 
• arthralgia, arthritis, lymphadenopathy, or conjunctivitis; and 
• lack of epidemiologic linkage to a laboratory-confirmed case of rubella; and 
• noncontributory or no serologic or virologic testing. 
Confirmed: A case with or without symptoms who has laboratory evidence of rubella 
infection confirmed by one or more of the following: 
• isolation of rubella virus; or 
• detection of rubella-virus specific nucleic acid by polymerase chain reaction; or 
• significant rise between acute-and convalescent-phase titers in serum rubella 
immunoglobulin G antibody level by any standard serologic assay; or 
• positive serologic test for rubella immunoglobulin M (IgM) antibody*,† 
OR 
An illness characterized by all of the following: 
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• acute onset of generalized maculopapular rash; and 
• temperature greater than 99.0° F or 37.2° C; and 
• arthralgia, arthritis, lymphadenopathy, or conjunctivitis; and 
• epidemiologic linkage to a laboratory-confirmed case of rubella. 
* Not explained by MMR vaccination during the previous 6-45 days. 
† Not otherwise ruled out by more specific testing in a public health laboratory. 
Congenital Rubella Syndrome Surveillance Case Definition (2009)8 
Suspected: An infant who does not meet the criteria for a probable or confirmed case 
but who has one or more of the following findings: 
• cataracts, 
• congenital glaucoma, 
• congenital heart disease (most commonly patent ductus arterious or peripheral 
pulmonary artery stenosis), 
• hearing impairment, 
• pigmentary retinopathy, 
• purpura, 
• hepatosplenomegaly, 
• jaundice, 
• microcephaly, 
• developmental delay, 
• meningoencephalitis, or 
• radiolucent bone disease. 
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Probable: An infant who does not have laboratory confirmation of rubella infection 
but has at least two of the following, without a more plausible etiology: 
• cataracts or congenital glaucoma, 
• congenital heart disease (most commonly patent ductus arterious or peripheral 
pulmonary artery stenosis), 
• hearing impairment, or 
• pigmentary retinopathy; 
OR 
An infant who does not have laboratory confirmation of rubella infection but has at 
least one or more of the following, without a more plausible etiology: 
• cataracts or congenital glaucoma, 
• congenital heart disease (most commonly patent ductus arterious or peripheral 
pulmonary artery stenosis), 
• hearing impairment, or 
• pigmentary retinopathy; 
AND one or more of the following: 
• purpura, 
• hepatosplenomegaly, 
• microcephaly, 
• developmental delay, 
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• meningoencephalitis, or 
• radiolucent bone disease. 
Confirmed: An infant with at least one of the symptoms clinically consistent with 
congenital rubella syndrome listed above; and laboratory evidence of congenital 
rubella infection demonstrated by: 
• isolation of rubella virus, or 
• detection of rubella-specific immunoglobulin M (IgM) antibody, or 
• infant rubella antibody level that persists at a higher level and for a longer period 
of time than expected from passive transfer of maternal antibody (i.e., rubella titer 
that does not drop at the expected rate of a two-fold decline per month), or 
• a specimen that is PCR-positive for rubella virus. 
Note: In probable cases, either or both of the eye-related findings (cataracts and 
congenital glaucoma) count as a single complication. In cases classified as infection 
only, if any compatible signs or symptoms (e.g., hearing impairment) are identified 
later, the case is reclassified as confirmed. 
Epidemiologic Summary 
One case of rubella was reported in Kentucky between 2005 and 2015.  
Notes 
i: CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of 
measles, rubella, and congenital rubella syndrome and control of mumps. 
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Recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR 1998;47(No. RR-8).  
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Tetanus 
Background2 
Tetanus is caused by the toxin tetanospasmin produced by the spore-forming 
bacterium Clostridium tetani. The spores are often found in soil and manure. C. tetani is 
transmitted through a contaminated wound. It cannot be spread person to person. The 
toxin produced binds in the central nervous system causing the characteristic symptoms 
of muscle spasms and stiffness, with the first sign often being lockjaw. The incubation 
period can range from 3 to 21 days, with the average being 8 days. Generally, the further 
the site of the injury is from the central nervous system, the longer the incubation period. 
Higher chances of death are associated with shorter incubation periods.  
Everyone should receive tetanus toxoid, which is available in combination with 
multiple other vaccines. These include pediatric diphtheria-tetanus toxoid (DT), adult 
tetanus-diphtheria (Td), and with pertussis vaccine as well as diphtheria toxoid as DTaP 
or Tdap. Children should receive 4 doses of DTaP by 15 to 18 months of age, with a 
booster before entering school between the ages of 4 and 6. The next booster, 
recommended to be Tdap, is given at age 11 or 12. Boosters of Td are then recommended 
every 10 years to maintain protective antitoxin titers.  
Epidemiology 
Tetanus toxoid was first produced in 1924 and introduced into routine childhood 
vaccines in the late 1940s.2 Reported incidence rates of tetanus declined steadily 
following the introduction of the vaccine, falling to an all time low of 18 reported cases 
in 2009.i  
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Surveillance Case Definition (2009)8 
Tetanus clinical case definition 
In the absence of a more likely diagnosis, an acute illness with muscle spasms or 
hypertonia and diagnosis of tetanus by a health care provider; or death, with tetanus 
listed on the death certificate as the cause of death or a significant condition 
contributing to death. 
Case classification 
Probable: A clinically compatible case, as reported by a healthcare professional. 
There is no definition for confirmed tetanus. 
Epidemiologic Summary 
There were two case of tetanus reported in Kentucky between 2005 and 2015.  
Notes 
i: CDC. Notifiable diseases and mortality tables. MMWR 2012;61:ND 719–32.  
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Varicella 
Background2 
Varicella, or chicken pox, is caused by the DNA virus varicella zoster virus (VZV). 
This virus can persist after the primary infection in the sensory nerve ganglia. 
Reactivation of the latent VZV results in herpes zoster, or shingles. The incubation period 
is 14 to 16 days with a range of 10 to 21 days. Primary infection with VZV presents with 
a generalized, pruritic, maculo-papulovesicular rash that usually appears first on the head 
and then the trunk and extremities. Over the course of several days, lesions will develop 
in several crops and then eventually crust over. The risk of complications from varicella 
are greater for persons older than 15 years, less than 1 year, those with compromised 
immune systems, and newborns of women whose rash started between 5 days before 
delivery to 2 days after delivery. VZV is transmitted person to person through infected 
secretions from the respiratory tract. Varicella can also be transmitted by direct contact 
with lesions. It is a highly contagious disease. Herpes zoster occurs mainly in older adults 
and is uncommon in children. Herpes zoster presents with a painful rash that is unilateral 
and follows the distribution of a sensory nerve. 
The vaccine was licensed in 1995 and there are currently 3 VZV containing vaccines 
licensed in the United States: a varicella vaccine, a measles-mumps-rubella-varicella 
(MMRV) combination vaccine, and a herpes zoster vaccine. The varicella vaccine is 
recommended for all children at 12 through 15 months with a second dose given between 
4 and 6 years of age. The herpes zoster vaccine is approved for persons over 50 years, but 
not recommended for individuals under 60 years of age.  
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Epidemiology 
It is estimated that there were 10,632 hospitalizations due to varicella each year from 
1988 to 1995.i There were an average of 105 deaths due to varicella reported each year 
from 1970 to 1994.i Since the introduction of the vaccine, hospitalizations due to 
varicella have declined 70% and deaths due to varicella have declined 88%.i  
Surveillance Case Definition (2009)8 
Varicella Clinical Case Definition 
An illness with acute onset of diffuse (generalized) maculopapulovesicular rash 
without other apparent cause. In vaccinated persons who develop varicella more than 
42 days after vaccination (breakthrough disease), the disease is usually mild with 
fewer than 50 skin lesions and shorter duration of illness. The rash may also be 
atypical in appearance (maculopapular with few or no vesicles). 
Varicella Case Classification 
Probable: A case that meets the clinical case definition but is not laboratory 
confirmed nor epidemiologically linked to another probable or confirmed case 
Confirmed: A case that is laboratory confirmed or that meets the clinical case 
definition and is epidemiologically linked to a confirmed or a probable case 
Note: Two probable cases that are epidemiologically linked are considered 
confirmed, even in the absence of laboratory confirmation. 
Epidemiologic Summary 
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There were no cases reported in the state from 2005 to 2015 because varicella was not 
reportable in the state of Kentucky during these years.  
Notes 
i: CDC. Use of combination measles, mumps, rubella, and varicella vaccine: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). 
MMWR 2010;59(No. RR-3):1–12. 
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Discussion 
Hepatitis B, Acute 
From 2005 to 2015, rates of acute hepatitis B in Kentucky have been very 
different from the rates seen nationally. Rates have been higher in Kentucky than in the 
United States for every year except 2005. The rate in the United States has remained 
stable over this time period, while the rate in Kentucky has increased, with some years 
being nearly four times the national rate.12 These differences highlight the importance of 
state level surveillance because the high rates of this disease in Kentucky would not have 
been identified from only looking at or calculating national rates.9 
Over the ten-year period, the highest rate was seen in the 30-39 age group with 
7.76 cases per 100,000. This rate is 138.25 times the rate of acute hepatitis B compared to 
those in the <19 age group. The second highest rate was seen in the 40-49 age group with 
6.04 cases per 100,000. This is 107.58 times the rate of acute hepatitis B compared to 
those in the <19 age group. These high rates of acute hepatitis B in older age groups have 
been seen in other studies of the disease9,11 and could be due to low hepatitis B vaccine 
coverage and past changes in vaccine recommendations. Hepatitis B vaccine coverage is 
low among adults19 and routine hepatitis B vaccination was recommended for infants 
starting in 1991 and for children ≤18 in 1999.2 This means that portions of these age 
groups, such as individuals who were 34 or older in 2015, would be too old to have 
received these routine vaccinations, putting them at risk of infection.  
 There were a large proportion of missing and unknown values for race and 
ethnicity. For race, 35% of cases had a missing or unknown value. For ethnicity, 43% of 
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cases had a missing or unknown value. There were also small numbers in multiple 
categories, which contributed to the difficulty in drawing conclusions. The highest rate 
was seen in American Indians/Alaska Natives, with 2.89 cases per 100,000 although this 
rate was not significantly different from the reference category, whites. The second 
highest rate was seen in whites, with 1.95 cases per 100,000. Not Hispanic/Latino had the 
highest rate with 1.68 cases per 100,000, two times the rate of Hispanic/Latino. 
Compared to females, males had 1.35 times the rate of acute hepatitis B.  
 To look at the geographic distribution of rates of hepatitis B in the state area 
development districts were used. Big Sandy had the highest rate with 12.21 cases per 
100,000, followed by Cumberland Valley with 7.15 cases per 100,000, and Kentucky 
River with 5.12 cases per 100,000. The seven area development districts with the highest 
rates (Big Sandy, Cumberland Valley, Kentucky River, Northern Kentucky, Gateway, 
Fivco, and Buffalo Trace) are all located in the eastern portion of the state, with the 
exception of Northern Kentucky. Of these eastern area development districts, the lowest 
rate was seen in Buffalo Trace with 4.20 cases per 100,000. This rate is still over twice as 
high as the next highest district. Although risk factor data was not available for this 
report, this could be related to injection drug use which has been seen in other studies.11,20 
More research needs to be done to further understand this relationship, specifically in 
rural areas such as eastern Kentucky.  
 There is some evidence that hepatitis B peaks in the spring and summer.21 This 
could be important for future study and prevention efforts. 
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Pertussis 
Rates of pertussis in Kentucky fluctuated between 2005 and 2015, hitting a low of 
1.20 cases per 100,000 in 2007 and a high of 12.34 cases per 100,000 in 2012. These 
fluctuations in rates makes sense given that pertussis peaks in the United States in 3 to 5 
year cycles.15 Over this same time period, rates of pertussis also fluctuated nationally. 
The lowest and highest rates in the United States were also seen in those same years, with 
3.49 cases per 100,000 in 2007 and 15.4 cases per 100,000 in 2012.13 This was the 
highest number of cases of pertussis reported in the United States since 1955.22 This large 
increase could be due to multiple factors. These include increased awareness, increased 
use of polymerase-chain-reaction (PCR) for diagnosis of pertussis, as well as potential 
genetic changes in the bacterium that causes pertussis.23 
 Over the ten-year period, the highest rate was seen in the <1 age group with 81.70 
cases per 100,000. This rate is 64.83 times the rate of pertussis compared to those in the 
>18 age group. The second highest rate was seen in the 1-3 age group with 22.62 cases 
per 100,000, a rate 17.95 times the rate seen in the >18 age group. This is reasonable 
because pertussis is the greatest risk to very young people, especially infants under one 
year.2,15 The next highest rate was seen in the 7-9 age group with 22.05 cases per 
100,000, a rate 17.50 times the rate of those >18. Differences in immunity conferred by 
the previously used whole cell vaccine and the currently used acellular pertussis vaccine 
help explain the increase in the rate of pertussis in older groups. Immunity from the 
acellular pertussis vaccine wanes more quickly, resulting in adolescents who have been 
previously vaccinated becoming susceptible to pertussis again.15,23 Looking at the rate of 
pertussis by age and year shows large variability between age groups in each year, as well 
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as large variability between age groups across time. A similar pattern is seen with the <1 
age group consistently having the highest rate of pertussis. Beginning in 2008, the second 
highest rate is more often seen in an age group other 1-3.  
 A large portion (42%) of cases had missing or unknown values for race. Whites 
had the highest rate of pertussis with 3.36 cases per 100,000, followed by blacks/African 
Americans with 2.09 cases per 100,000. A large portion (49%) of cases also had missing 
or unknown values for ethnicity. Hispanics/Latinos had higher rates of pertussis with 3.54 
cases per 100,000 compared to non Hispanics/Latinos with 2.84 cases per 100,000, but 
the difference between these rates was not significant. Females had a rate of 5.83 cases 
per 100,000, which was higher than the 5.12 cases per 100,000 seen in males.  
 A study of vaccine coverage of children enrolled in kindergarten for the 2015-
2016 school year found 93.9% had received 5 doses of DTaP. Median vaccination 
coverage for DTaP in the country was 94.2%.24 It has been shown that pertussis peaks in 
the summer, though the reason behind this seasonality is not well understood.25 
Surveillance in Kentucky 
 The main issue with VPD surveillance in Kentucky is a lack of completeness, 
especially relating to demographic variables like race and ethnicity. The state would 
benefit greatly from an increase in the collection of this demographic data. The large 
number of missing values for race and ethnicity made it difficult to draw conclusions 
about which groups truly had the highest rates of these diseases. Having better data 
would allow for a more complete picture of the distribution of disease in the state, which 
would in turn allow for better identification of high risk groups. This is especially 
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important for diseases like hepatitis B, where what is happening in Kentucky is very 
different than what is happening in the rest of the United States. Since the overall rates in 
the state vary greatly from the national rates, having a better idea of the demographic 
distribution in the state would be helpful to compare to the demographic distribution of 
the disease in the country overall. This could help to identify why rates in Kentucky are 
higher. 
The three different methods of surveillance (passive, active, and sentinel) each 
offer different advantages and disadvantages. Passive surveillance relies on reports of 
certain diseases to public health officials from places like hospitals, health care providers, 
and laboratories. The National Notifiable Disease Surveillance System (NNDSS) is a 
passive surveillance system,8 and this is the method most commonly used for VPD 
surveillance. This type of surveillance can cover large areas, like an entire state or 
country, but the reports are not always complete. This was a large part of the problem 
with the data used in this report. Active surveillance can provide a more complete and 
timely picture of the number of cases, but is more expensive to perform than passive 
surveillance since it involves going out and looking for cases. It is often in outbreak 
situations, but is not as plausible for long-term disease surveillance. Sentinel surveillance 
uses specific sites where data is collected and then generalized to a larger population.8 
While this is valuable in some situations, it does not apply well to situations where actual 
number of cases and distribution of these cases is important, such as VPD surveillance. 
 Data capture could potentially be improved with certain design changes to the 
surveillance system. The use of an electronic system to submit case reports and forms 
that cannot be submitted without certain critical information included could help with the 
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high number of missing demographic variables. Cases could also be cross referenced 
with other sources of data that may have more complete information relating to 
demographics, such as birth certificates.   
 Collecting other information such as vaccination status or specific risk factors 
would also allow for more meaningful conclusions to be drawn. For example, if data 
about the vaccination status of the pertussis cases were available, it could point to 
whether the increase in cases in certain years was related to unvaccinated individuals or 
vaccine failure in those who were previously vaccinated. Collecting data about some key 
risk factors for hepatitis B, such as injection drug use and number of sexual partners, 
could help improve the public health response to this disease. The answers to these kinds 
of questions are very important, especially when it comes to focusing public health 
efforts to continue to prevent these diseases. 
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